Literature DB >> 3335919

In vivo chemistry of iofetamine HCl iodine-123 (IMP).

R M Baldwin1, J L Wu.   

Abstract

Application of chemical methods for characterizing the in vivo behavior of iofetamine HCI 123I (IMP) has shed light on the metabolism of iofetamine in animals and humans. A successful technique consists of ethyl acetate extraction of the metabolites from tissue samples acidified with perchloric acid, separation of the mixture by high performance liquid chromatography, and quantitation of the radioactive components with a sensitive scintillation detector. Metabolism of iofetamine HCI 123I proceeds sequentially from the N-isopropyl group on the amphetamine side chain. The first step, dealkylation to the primary amine p-iodoamphetamine (PIA), occurs readily in the brain, lungs, and liver; activity in the brain and lungs consists of only IMP and PIA even 24 hr after administration. The rate-limiting step appears to be deamination to give the transitory intermediate p-iodophenylacetone, which is rapidly degraded to p-iodobenzoic acid and conjugated with glycine in the liver to give the end product of metabolism, p-iodohippuric acid, which is excreted through the kidneys in the urine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335919

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  Prolonged lung retention of 123I-IMP in pulmonary fibrosis.

Authors:  H Ikeda; M Itasaka; K Takahashi; A Komatani
Journal:  Ann Nucl Med       Date:  1992-08       Impact factor: 2.668

2.  New design of N-isopropyl-p-[123I]iodoamphetamine (123I-IMP) lung imaging in the patient with lung cancer.

Authors:  E Tanaka; M Mishima; K Kawakami; N Sakai; N Sugiura; T Taniguchi; M Ohi; H Itoh; K Kuno
Journal:  Ann Nucl Med       Date:  1995-11       Impact factor: 2.668

3.  The influence of age on N-isopropyl-p-[123I]iodoamphetamine accumulation in the human heart.

Authors:  M Nakajo; Y Nakabeppu; S Iwashita; S Shinohara
Journal:  Ann Nucl Med       Date:  1990-07       Impact factor: 2.668

4.  Prolonged lung retention of 123I-IMP in pulmonary disease.

Authors:  H Ikeda; M Mariko; M Komatsu; K Takahashi; S Yasui; K Takahashi
Journal:  Eur J Nucl Med       Date:  1989

5.  Differentiation of bronchogenic carcinoma from secondary changes, obstructive pneumonitis and/or collapse by I-123 IMP lung imaging.

Authors:  M Nakajo; N Uchiyama; J Shimada; S Shinohara; A Iriki; Y Hirotsu; K Egawa; H Fukunaga; Y Norimatsu
Journal:  Ann Nucl Med       Date:  1990-03       Impact factor: 2.668

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.